Brief: Cantargia Receives Approval To Start Cestafour Clinical Study

Cantargia AB

10/09/2021 12:32

Sept 10 (Reuters) - Cantargia AB  CANTA.ST :
    * CANTARGIA RECEIVES REGULATORY APPROVAL TO START CESTAFOUR
CLINICAL STUDY WITH NADUNOLIMAB IN COMBINATION WITH CHEMOTHERAPY
    * CANTARGIA AB - FIRST PATIENT IS ESTIMATED TO BE ENROLLED
IN
SEPTEMBER/OCTOBER 2021.
    * CANTARGIA AB - STUDY WILL BE CONDUCTED AT APPROXIMATELY 20
CLINICAL CENTERS IN EUROPE AND WILL INCLUDE UP TO A TOTAL OF 165
PATIENTS.

Source text for Eikon:  ID:nWkr3ptxyd 
Further company coverage:  CANTA.ST 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))